Patricia Ogilvie graduated in medicine at the University of Würzburg, Germany with an MD thesis in clinical biochemistry. After the residency in dermatology at universities in Germany and Switzerland, she became a postdoctoral research fellow of the German Research Foundation and spent several years in the field of immunology and cell signalling research at international research institutions. Her research projects in The Institute for Research in Biomedicine (IRB) in Bellinzona, Switzerland were supervised by the Nobel prize Laureate Renato Dulbecco (ƚ). In her active research work, Patricia described several fundamental mechanisms of inflammation that have been found relevant also in the context of understanding basic aging mechanisms: She described the development-dependant expression of an isoform of Nitric-oxide synthase in the brain (Ogilvie et al., FASEB 1995). Later, she was the first to overserve an antagonistic activity of Eotaxin (Ogilvie et al. Blood 2001), a chemokine essential in the composition of inflammatory infiltrates but also- most recently found- of instrumental importance for neurodegeneration and aging. She was able to discover the unique intracellular signal- transduction pathways used by chemokine antagonists (Ogilvie et al. Blood 2003), and was later the first to demonstrate that chemokines can act as active chemo-repellents (Ogilvie et al. 2004, Journal of Immunology). Her contribution to understanding fundamental principles of inflammation and aging are still frequently cited in the contemporary scientific literature.
In her early career as a clinical dermatologist, she participated in the first clinical trials for the approval of Botulinumtoxin in Germany in 1995. Dr Ogilvie received the German board certification for dermatology and allergology in 2003. In 2004, she founded Skin Concept Munich, which comprises two private clinics for dermatology and laser medicine and includes a centre for clinical research.
Dr Ogilvie is an international speaker and trainer for botulinum toxin and injectable fillers, a principal investigator in clinical trials, and a member of the National Guideline Conferences for Botulinum Toxin and Injectable Fillers. She shares her expertise in Clinical and cosmetic Dermatology at scientific advisory boards and has also authored over 70 scientific papers in the fields of biochemistry, immunology, clinical dermatology and aesthetic medicine. She is scientific consultant for international cosmetic companies and a media spokesperson for skin care and hair care producers. Dr. Ogilvie is member of the editorial board of several scientific journals. Since 2019, Patricia is the co-founder of “Science of Aging”, a multi-speciality faculty meeting and community with research focus on the molecular understanding of aging and longevity. She is a member and scientific advisor of the “Reverse Aging Board” of DIOR science/LVMH recherché, a multidisciplinary selected group of world-renowned scientists in basic and translational aging research. She is in the board of directors of several international conferences in aesthetic medicine.
Her research focus in aesthetic medicine is neuromodulators, where she participated in numerous clinical trials, novel injectable fillers, and attractiveness research. She was the national lead investigator and co-authored the pivotal Phase 3 study of Botox® for the combined treatment of upper facial lines, the approval trials of a novel HA filler for chin and jawline as well as an innovative injectable for improving skin quality, the pivotal trials on novel toxins, new neurotoxin indications such as platysma bands and masseter prominence, as well as innovative injectable fillers and lasers/energy-based devices. She leads a research unit in her clinic dedicated to investigating novel cosmetic ingredients. She is passionate about measuring and optimising patient-reported outcomes and psychological impact to patients with aesthetic treatments. Most currently, her special interest in research and clinical treatment is promoting female health span through aesthetic and functional medicine.
